

Malaria Prevention in Travelers 2006

Patrick C. Lowry, MD, MPH

The Radiation Emergency Assistance Center and
Training Site (REAC/TS)

ORISE/ORAU

lowryp@orau.gov

<http://orise.orau.gov/reacts/>

Acknowledgement:

Jay Keystone MD MSc(CTM)

Centre for Travel and Tropical Medicine


Toronto General Hospital

Professor of Medicine

University of Toronto, Canada

World's Most Important Parasitic Disease Is Malaria

Deaths caused by leading infectious diseases in 1998²




- 300 to 500 million cases of malaria reported each year¹
- 1.1 million deaths in 1998, compared with 2.3 million from AIDS²

¹Taylor TE, Strickland GT. Infections of the blood and reticuloendothelial system. In: Strickland GT, ed. *Hunter's Tropical Medicine and Emerging Infectious Diseases*. 8th ed. Philadelphia, Pa: W.B. Saunders Company; 2000: 614-643.

²World Health Organization. 1999 Infectious Diseases Report. Graph 5. Available at: <http://www.who.int/infectious-disease-report/pages/graph5.html>. Accessed May 23, 2002.



FIGURE 1. Number of malaria cases among U.S. and foreign civilians — United States,* 1973–2002†



* Includes Puerto Rico, Guam, and the U.S. Virgin Islands.
† The substantial increase in the number of cases reported for 1980 primarily reflects cases diagnosed among immigrants from Southeast Asia.

The NEW ENGLAND JOURNAL *of* MEDICINE

ESTABLISHED IN 1812

JANUARY 12, 2006

VOL. 354 NO. 2

Spectrum of Disease and Relation to Place of Exposure among Ill Returned Travelers

David O. Freedman, M.D., Leisa H. Weld, Ph.D., Phyllis E. Kozarsky, M.D., Tamara Fisk, M.D.,*
Rachel Robins, M.D., Frank von Sonnenburg, M.D., Jay S. Keystone, M.D., Prativa Pandey, M.D.,
and Martin S. Cetron, M.D., for the GeoSentinel Surveillance Network†

Imported malaria USA 2003


N= 783 MMWR 2005;54:25-39

Category	Percent
VFRs	53.9
Tourism	12.5
Missionary	9.2
Business	7.5
Student	3.8

Percent Fever in Returned Travelers

N=3907 NEJM 2005;354:

Etiology	Carib	CAm	SAm	SSA	SA	SEA
malaria	<1	13	13	62	14	13
dengue	23	12	14	<1	14	32
mono	7	7	8	1	2	3
rickettsia	0	0	0	6	1	2
Salmon.	2	3	2	<1	14	3



Malaria chemoprophylaxis considerations

- 1. Is the traveler going to a malarious area?**
- 2. Will the traveler be *exposed* to malaria?**
- 3. Is the area chloroquine or mefloquine resistant?**
- 4. Are there any contraindications to antimalarial use (pregnancy, cost etc) ?**

Malaria chemoprophylaxis considerations


- 5. What is travelers experience with antimalarials?**
- 6. What is the duration of antimalarial use?**
- 7. Is there any indication for presumptive self-tx?**

Drug Resistant malaria


- Chloroquine sensitive *P. falciparum*
- Chloroquine resistant *P. falciparum*
- Mefloquine resistant *P. falciparum*
- Chloroquine resistant *P. vivax*,
malariae
- Primaquine tolerant *P. vivax*

Life Cycle of Malaria

Human Host



Prevention of malaria



**personal
protection
measures**

antimalarials

Personal Protective Measures

Relative Duration of Action of Insect Repellents

Ingredient	mean	range
DEET 5%	1h	0.75 2h
DEET 23%	5h	3.5 – 6h
DEET 99%	10h	8 - 12h
Citronella 10%	14 min.	7 – 60m



*Except: ultrathon & Sawyer CR DEET: 20-30%= 10-12 hr



Optimum combination = 99.99% protection
DEET (skin) + Permethrin (clothing)

SOAK FOR 2 HOURS
EFFECTIVE FOR 6 WEEKS

INSECT REPELLENT PROTECTIVE TREATMENT
 FOR CLOTHING APPLICATION
 DO NOT APPLY TO SKIN
 REPELS & KILLS TICKS, CHIGGERS,
 MITES AND MOSQUITOES
 Repels and Kills Ticks which may carry
 Lyme disease and Rocky Mountain Spotted Fever

ACTIVE INGREDIENT: Permethrin*	0.50%
INERT INGREDIENTS:	99.50%
TOTAL:	100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-dichloroethyl)
 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

CONVENIENT SPRAY
EFFECTIVE FOR 6 WEEKS

REPELS & KILLS
 TICKS AND MOSQUITOES
 A TREATMENT FOR CLOTHING. DO NOT APPLY TO SKIN

ACTIVE INGREDIENTS:

INERT INGREDIENTS:

TOTAL:

NET CONTENTS 9 OZ.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

REPELS & KILLS TICKS
 AND MOSQUITOES

EFFECTIVE FOR 2 WEEKS
 ODORLESS AFTER APPLICATION
 NON-STAINING

A TREATMENT FOR CLOTHING
 DO NOT APPLY TO SKIN

ACTIVE INGREDIENT: Permethrin* 0.50%
 INERT INGREDIENTS 99.50%
 TOTAL 100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-
 dichloroethyl) 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

NET Contents: 15 oz

EFFECTIVE FOR 2 WEEKS

REPELS & KILLS TICKS AND MOSQUITOES
 A TREATMENT FOR CLOTHING. DO NOT APPLY TO SKIN

ACTIVE INGREDIENTS:

INERT INGREDIENTS:

TOTAL:

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

NET CONTENTS 6 OZ.

EFFECTIVE FOR 6 WEEKS

REPELS & KILLS TICKS AND MOSQUITOES
 A TREATMENT FOR CLOTHING. DO NOT APPLY TO SKIN

ACTIVE INGREDIENTS:

INERT INGREDIENTS:

TOTAL:

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

NET CONTENTS 6 OZ.

REPELS & KILLS TICKS
 AND MOSQUITOES
 EFFECTIVE FOR 2 WEEKS
 NON-STAINING
 APPLIES AND DRIES ODORLESS
 A TREATMENT FOR CLOTHING
 DO NOT APPLY TO SKIN

ACTIVE INGREDIENT: Permethrin* 0.50%
 INERT INGREDIENTS 99.50%
 TOTAL 100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-
 dichloroethyl) 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.


KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

Net Contents: 6oz

Bayrepel[®]

The new active
ingredient in AUTAN[®]

Picaridin



10%=3-5 hrs. 20%= 8-10hrs



7%

DEET use in Children

DEET recommendations 2003:

EPA and AAP:


30% DEET safe in children:

≥ age 2 months of age

Bayrepel[®]

The new active
ingredient in AUTAN[®]

Picaridin



10%=3-5 hrs. 20%= 8-10hrs



Safety of DEET in pregnancy

McGready, Am J Trop Med 2001;65:285-89

- **Thai study, RCT, DEET vs. control**
- **450 women/grp - 2nd & 3rd trimester**
- **use of DET over 18 wks**
- **200 gm DEET total = 1 litre of 20% DEET**
- **597/741 births followed x 1 yr.**

Safety of DEET in pregnancy (Cont'd.)

1. DEET detection:

- 0/30 samples in urine
- 4/50 samples of cord blood

2. Birth outcomes: no difference both groups

- neurological exam
- growth parameters
- congenital abnormalities (6 variable)
- survival @ birth & 1 year
- developmental delay



Optimum combination = 99.99% protection
DEET (skin) + Permethrin (clothing)

SOAK FOR 2 HOURS
EFFECTIVE FOR 6 WEEKS

INSECT REPELLENT PROTECTIVE TREATMENT
 FOR CLOTHING APPLICATION
 DO NOT APPLY TO SKIN
 REPELS & KILLS TICKS, CHIGGERS,
 MITES AND MOSQUITOES
 Repels and Kills Ticks which may carry
 Lyme disease and Rocky Mountain Spotted Fever

ACTIVE INGREDIENT: Permethrin*	0.50%
INERT INGREDIENTS:	99.50%
TOTAL:	100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-dichloroethyl)
 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

CONVENIENT SPRAY
EFFECTIVE FOR 6 WEEKS

REPELS & KILLS
 TICKS AND MOSQUITOES
 A TREATMENT FOR CLOTHING. DO NOT APPLY TO SKIN

ACTIVE INGREDIENT: Permethrin* 0.50%
 INERT INGREDIENTS: 99.50%
 TOTAL: 100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-dichloroethyl)
 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

NET CONTENTS 9 OZ.

REPELS & KILLS TICKS
 AND MOSQUITOES

EFFECTIVE FOR 2 WEEKS
 ODORLESS AFTER APPLICATION
 NON-STAINING

A TREATMENT FOR CLOTHING
 DO NOT APPLY TO SKIN

ACTIVE INGREDIENT: Permethrin* 0.50%
 INERT INGREDIENTS: 99.50%
 TOTAL: 100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-dichloroethyl)
 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

NET Contents: 15 oz

EFFECTIVE FOR 2 WEEKS

REPELS & KILLS TICKS AND MOSQUITOES
 A TREATMENT FOR CLOTHING. DO NOT APPLY TO SKIN

ACTIVE INGREDIENT: Permethrin* 0.50%
 INERT INGREDIENTS: 99.50%
 TOTAL: 100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-dichloroethyl)
 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

NET CONTENTS 6 OZ.

EFFECTIVE FOR 6 WEEKS

REPELS & KILLS TICKS AND MOSQUITOES
 A TREATMENT FOR CLOTHING. DO NOT APPLY TO SKIN

ACTIVE INGREDIENT: Permethrin* 0.50%
 INERT INGREDIENTS: 99.50%
 TOTAL: 100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-dichloroethyl)
 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.

KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

NET CONTENTS 6 OZ.

REPELS & KILLS TICKS
 AND MOSQUITOES

EFFECTIVE FOR 2 WEEKS
 NON-STAINING
 APPLIES AND DRIES ODORLESS
 A TREATMENT FOR CLOTHING
 DO NOT APPLY TO SKIN

ACTIVE INGREDIENT: Permethrin* 0.50%
 INERT INGREDIENTS: 99.50%
 TOTAL: 100.00%

* (3-phenoxyphenyl) methyl (+) cis/trans 3-(2,2-dichloroethyl)
 2,2-dimethylcyclopropanecarboxylate
 Cis/Trans Ratio: min. 35% (+) cis and max. 65% (+) trans.


KEEP OUT OF REACH OF CHILDREN
CAUTION SEE BACK PANEL FOR ADDITIONAL
 PRECAUTIONARY STATEMENTS

Net Contents: 6oz

Prophylaxis with Antimalarials

Life Cycle of Malaria

Human Host



Malaria Chemoprophylaxis

Chloroquine Sensitive malaria: 😊

chloroquine

Chloroquine Resistant Malaria 😞

DOC

{
mefloquine
doxycycline
atovaquone/proguanil
primaquine

Chloroquine

- 4-aminoquinolone
- Reduced efficacy globally to *P.falciparum*
- 500 mg weekly beginning 1-2 weeks prior and 4 weeks after exposure
- GI upset, keratopathy ,
- pruritus in African Americans
- Safe in pregnancy

Drugs for Chloroquine Resistant Malaria

Drug	Advantage	Disadvantage
Mefloquine <i>Lariam</i>	Weekly Moderate cost \$\$	Neuropsychiatric Adverse Drug Reactions (ADR) 1-2 wks pre;4 wks post

Now hear this.....the M word!

**If you prescribe mefloquine
without discussing adverse
events *and* alternative
chemoprophylactic agents,
you will likely meet**

between the patients and the control groups. Also, no significant difference was found between mefloquine levels in

No correlation between ADR's and drug levels

Mefloquine (Lariam®)

- ❖ Most adverse effects 1-3rd dose
- ❖ start **4 weeks** before exposure
or **loading dose** : 1 tab daily x 3
days then weekly thereafter

Curses, Madness, and Mefloquine

OLADIPO KUKOYI, M.D.

CAROLINE P. CARNEY, M.D., M.Sc.

Mefloquine is a quinoline-methanol compound structurally similar to quinine. Because of its efficacy and once-weekly dosing, mefloquine is a good choice for malaria prophylaxis for travelers to areas with chloroquine-resistant *Plasmodium falciparum* malaria. It is recommended as the drug of choice by most authorities.¹ It has a wide volume of distribution, can cross the blood-brain

barrier,
half-life
such as
(described

effects. Mefloquine has rarely been linked to more severe mental status changes such as psychosis.³⁻⁵ This report presents the case of a young woman who developed severe psychosis after re-exposure to mefloquine and whose treatment was complicated by sociocultural issues.

vinced that her husband was the Devil. She started to eat from garbage cans, as she believed her food was being poisoned.

Her husband's emigration to the United States was considered a sign of success in his home community. It was proposed by her in-laws that people jealous of his success had cast a spell on his wife to drive her insane. The

Tolerance to mefloquine once does not mean tolerance to the drug the second time

prayer and fasting commenced. After several days without improvement in his wife's symptoms, Ms. A's husband surreptitiously took her and their 3-year-old daughter and boarded a flight back to the United States. The alleged culprit who had cast the spell had been identified, and he wanted to get as far away from her as possible. On the

Drugs for Chloroquine Resistant Malaria

Drug	Advantage	Disadvantage
Doxycycline	Lowest cost \$	Daily; sun burn* ; GI; vaginal yeast infection ☹ 1day pre,4 wks post (fluconazole) ☹

Sunburn: 5-15%

Drugs for Chloroquine Resistant Malaria

Drug	Advantage	Disadvantage
Malarone <i>Atovaquone</i> <i>/proguanil</i>	Safety Convenience 1 day pre;7 days post	Highest Cost \$\$\$ headache, GI upset, insomnia; Daily?

Tolerability of antimalarials: RDB 4 arm study % Neuropsychological AE's*

Schlagenhauf BMJ 2003;327:1078

Adverse event	Mefloquine N=153	Doxycycline N=153	Atov/prog N=154
severe	5	1	3
moderate	37	24	20
all events	77	69	67

***headache, vivid dreams, dizziness, depression, anxiety, insomnia**


Drugs for Chloroquine Resistant Malaria

Drug	Advantage	Disadvantage
Primaquine	Low cost \$\$ 1 day pre; 3 days post	*G6PD level required Daily; take with food

*Off label

Life Cycle of Malaria

Human Host



Primaquine Prophylaxis

- 8-aminoquinolone
- tissue schizonticide → causal prophylaxis
- **Dose:** 30 mg (base) = 2 tabs/day, 1 day before and 3 days after exposure
- **Efficacy:** 85-95% (Pf + Pv) in 3 studies:
Irian Jaya, Kenya & Colombia

Primaquine Prophylaxis in non-immunes

	Fryauff	Soto	Baird
Duration (weeks)	52	16-18	20
No. in primaquine group	43	122	97
P.Falciparum PE (95%CI)	94 (61-99)	94 (78-99)	88 (48-97)
P.Vivax PE (95%CI)	90 (65-99)	84 (57-96)	92 (37-99)
All malaria PE (95%CI)	92 (77-99)	89 (75-96)	93 (71-98)

Primaquine Prophylaxis

Cont'd.

- **Adverse events:** GI upset, met Hb
- **C/I:** G6PD deficiency, pregnancy
- **Helpful hints:** G6PD screen, take with food


Soto, Ann Int Med 1998; 129:241,
Fryauff, Lancet 1995;346:1190

Percent G6PD deficiency in US military personnel


<i>Ethnicity</i>	<i>NO.</i>	<i>F</i>	<i>M</i>	<i>Total</i>
Native American	604	0.9	0.8	0.8
Asian	2123	0.9	4.3	3.6
Black	11,276	4.1	12.2	10.2
Hispanic	5304	1.2	2.0	1.9
White	42,162	0.0	0.3	0.3

M:F = 4+:1

G6PD deficiency in male US military personnel by WHO level of deficiency.




G6PD deficiency in female US military personnel by WHO level of deficiency.




Life Cycle of Malaria

Human Host



Post –exposure primaquine prophylaxis: > 3 months stay? 30 mg /day x 14 days



Malaria and Pregnancy & Children

Pregnancy:

- ❖ CSPF: cloroquine
- ❖ CRPF: • mefloquine safe in 2nd trimester, probably 1st

Children:

- ❖ Prophylaxis down to age zero

A Randomized Comparison of Artesunate-Atovaquone-Proguanil versus Quinine in Treatment for Uncomplicated Falciparum Malaria during Pregnancy

JID2005;192:846

Rose McGready,^{1,2,3} Elizabeth A. Ashley,^{1,2,3} Eh Moo,¹ Thein Cho,¹ Marion Barends,^{1,2} Robert Hutagalung,^{1,2} Sornchai Looareesuwan,² Nicholas J. White,^{2,3} and François Nosten^{1,2,3}

¹Shoklo Malaria Research Unit, Mae Sot, and ²Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;

³Centre for Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom

Background. There is no safe, practical, and effective treatment for pregnant women infected with multidrug-resistant *Plasmodium falciparum*.

39 women Tx 2nd-3rd trimester
No birth defects @ 1year

interval, 1.7–29.2]; $P = .001$). There were no significant differences in birth weight, duration of gestation, or congenital abnormality rates in newborns or in growth and developmental parameters of infants monitored for 1 year.

3 drugs of choice for Chloroquine Resistance

Drug	Indication
Mefloquine <i>Lariam</i>	Previous drug use Long-stay traveler Pregnancy, infancy
Doxycycline	Impecunious traveler Thai borders
Atovaquone/proguanil <i>Malarone</i>	Short-stay traveler Drug plan positive Thai borders

Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials

A. M. Dondorp^{1,2}, P. N. Newton^{2,3}, M. Mayxay³, W. Van Damme⁴, F. M. Smithuis⁵, S. Yeung^{1,2}, A. Petit⁵, A. J. Lynam⁶, A. Johnson⁷, T. T. Hien⁸, R. McGready^{1,9}, J. J. Farrar^{2,10}, S. Looareesuwan¹, N. P. J. Day^{1,2}, M. D. Green¹¹ and N. J. White^{1,2}

**21-92% (53%)
in 5 countries of SE Asia**

**If you take a proven
effective antimalarial
for chemoprophylaxis**

... It works!!

Evaluation of Reported Malaria Chemoprophylactic Failure among Travelers in a US University Exchange Program, 2002

CID 2004;39:1583-8

Louise M. Causer,¹ Scott Filler,¹ Marianna Wilson,¹ Stephen Papagiotas,² and Robert D. Newman¹

¹Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, and ²Georgia Division of Public Health, Atlanta, Georgia

(See the e

Backgr
and prom
investigat
were repo

Method
serologica

Results
Control a
therapy. T
reported
performed
that incor

Conclu

of drug resistance, but it could also result in unnecessary administration of antimalarial treatment. Health care providers and public health authorities must critically evaluate reports of chemoprophylactic failures and disseminate accurate information to travelers.

phylaxis
002, we
ana and
malaria
Disease
rence to
persons
aria was
ggesting

reports

**5 /25 university students
positive smears in Ghana:**



malaria antibodies 0/5

Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study

Hugh Reyburn, Redempta Mbatia, Chris Drakeley, Ilona Carneiro, Emmanuel Mwakasungula, Ombeni Mwerinde, Kapalala Saganda, John Shao, Andrew Kitua, Raimos Olomi, Brian M Greenwood, Christopher J M Whitty

BMJ 2004;329:1212

Abstract

Objective To study the diagnosis and outcomes in people admitted to hospital with a diagnosis of severe malaria in areas with differing intensities of malaria transmission.

Design Prospective study in 10 district hospitals in Tanzania

Setting 10 hospitals

Participants 4474 (2851 of whom had severe disease)

Main outcome outcome. Altitudes of residence (a proxy for transmission intensity) measured with a global positioning system.

Results Blood film microscopy showed that 2062 (46.1%) of people treated for malaria had *Plasmodium falciparum* (slide positive). The proportion of slide positive cases fell with increasing age and increasing altitude of residence. Among 1086 patients aged ≥ 5 years who lived above 600 metres, only 338 (31.1%) were slide positive, while in children < 5 years living in areas of intense transmission (< 600 metres) most (958/1392, 68.8%) were slide positive. Among 2375 people who

of district hospitals in Africa identified several problems with the organisation and planning of care.^{4,5}

Given the high proportion of admissions attributed to malaria, overdiagnosis of malaria and consequent neglect of alternative diagnoses could lead to avoidable morbidity and

**N=4,450 slides in 10 hospitals
40% false positive blood films**


of the people treated for malaria do not have the disease this will substantially increase the costs of change.

Accuracy of hospital diagnosis of malaria is likely to depend on the epidemiological probability of the disease (defined by intensity of malaria transmission and age of patients) and is important as most of the population of sub-Saharan Africa live in areas of low or moderate malaria transmission.⁷ We prospectively examined the diagnosis and outcome in all patients admitted and treated for severe or potentially complicated malaria during one year in 10 hospitals serving people for areas with

Tafenoquine: New 8-aminoquinoline antimalarial drug

- **Primaquine analogue**
- **approximately 10x efficacy and 1/10 toxicity of primaquine in animal studies**
- **very long half life (2-4 weeks)**
- **causes hemolysis in G6PD deficient persons**
- **apparently kills in both liver and blood**

WR238605 Prevention Trial 1997



Malaria morbidity:calculated attack rate per month without chemoprophylaxis

Solomon Is., PNG > 3%*

West Africa 2.4%

East Africa 1.2%

India 0.35%

SE Asia 0.1%

Latin America: 0.05%

**Chemo-
prophylaxis**

Cutoff Line

**Standby
medication**

Efficacy of the RTS,S/AS02A vaccine against *Plasmodium falciparum* infection and disease in young African children: randomised controlled trial **Lancet 2004;364:1411**



Pedro L Alonso, Jahnit Sacarlal, John J Aponte, Amanda Leach, Eusebio Macete, Jessica Milman, Inacio Mandomando, Bart Spiessens, Caterina Guinovart, Mateu Espasa, Quique Bassat, Pedro Aide, Opakua Ofori-Anyinam, Margarita M Navia, Sabine Corachan, Marc Ceuppens, Marie-Claude Dubois, Marie-Ange Demoitié, Filip Dubovsky, Clara Menéndez, Nadia Tomieporth, W Ripley Ballou, Ricardo Thompson, Joe Cohen

Lancet 2004; 364: 1411-20
See [Comment](#) page 1380
Centre de Salut Internacional,
Hospital Clínic/IDIBAPS,
Universitat de Barcelona

RCT Mozambique children n=2022
6 mo. PE 1st clin episode: 30%
6 mo. PE severe malaria : 58%

protocol analysis. Vaccine efficacy for the first clinical episodes was 29.9% (95% CI 11.0-44.8; p=0.004). At the end of group 57.7% (31.4-55.9; p<0.0001).

Vaccine. 2005 Mar 18;23(17-18):2243-50

Mondlane, Maputo,
Mozambique (J Sacarlal);
Aide,
le
Aide,
(EMacete, I Mandomando,

Summary Malaria Prevention

- Fever from the tropics is malaria until proven otherwise... and a medical emergency!
- 3 equally effective prevention DOC and 1 alternative (primaquine); start mefloquine 1 mo. before exposure in new patients
- Frequent false positive blood films and counterfeit drugs in the developing world

Summary Malaria Prevention

- No antimalarial is 100% effective...NBce of personal protection measures
- DEET is the most effective & safe insect repellent, including infancy & pregnancy

Travel Medicine for Dummies

- Don't get bit
- Don't get hit
- Don't get lit
- Don't do "it"
- Don't eat shit!

David Smith 1986

Further Reading

- Franco-Paredes C, Santos-Preciado Problem pathogens: prevention of malaria in travellers. *Lancet Infect Dis.* 2006 Mar;6(3):139-49. Review.
- Meremikwu MM, Omari AA, Garner Chemoprophylaxis and intermittent treatment for preventing malaria in children. *Cochrane Database Syst Rev.* 2005 Oct 19;(4):CD003756.
- Knobloch J. Long-term malaria prophylaxis for travelers. *J Travel Med.* 2004 Nov-Dec;11(6):374-8.

Further Reading

- Shanks GD, Edstein MD. Modern malaria chemoprophylaxis.
Drugs. 2005;65(15):2091-110
- Baird JK. Effectiveness of antimalarial drugs.
N Engl J Med. 2005 Apr 14;352(15):1565-77
- Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers.
Infect Dis Clin North Am. 2005 Mar;19(1):185-210